Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension
Cwikla JB, Wolin EM, Pavel ME, Phan AT, Raderer M, Sedlackova E, Cadiot G, Capdevila J, Rindi G, Lombard-Bohas C, Liyanage N, Thanh XMT, Ruszniewski P, Caplin M (2017)
Publication Type: Conference contribution
Publication year: 2017
Journal
Book Volume: 28
Authors with CRIS profile
Involved external institutions
Montefiore Medical Center
United States (USA) (US)
University of Warmia and Mazury in Olsztyn
Poland (PL)
Royal Free Hospital
United Kingdom (GB)
Ipsen Pharma
France (FR)
Vall d'Hebron University Hospital / Hospital Universitari Vall d'Hebron
Spain (ES)
Robert Debré Hospital for Mothers and Children / Hôpital Robert Debré pour la mère et l'enfant
France (FR)
University of New Mexico (UNM) / Universidad de Nuevo México
United States (USA) (US)
Univerzita Karlova v Praze / Charles University in Prague
Czech Republic (CZ)
Hospices Civils de Lyon (CHU)
France (FR)
Medizinische Universität Wien
Austria (AT)
Catholic University of the Sacred Heart / Università Cattolica del Sacro Cuore
Italy (IT)
Beaujon Hospital / Hôpital Beaujon
France (FR)
United States (USA) (US)
University of Warmia and Mazury in Olsztyn
Poland (PL)
Royal Free Hospital
United Kingdom (GB)
Ipsen Pharma
France (FR)
Vall d'Hebron University Hospital / Hospital Universitari Vall d'Hebron
Spain (ES)
Robert Debré Hospital for Mothers and Children / Hôpital Robert Debré pour la mère et l'enfant
France (FR)
University of New Mexico (UNM) / Universidad de Nuevo México
United States (USA) (US)
Univerzita Karlova v Praze / Charles University in Prague
Czech Republic (CZ)
Hospices Civils de Lyon (CHU)
France (FR)
Medizinische Universität Wien
Austria (AT)
Catholic University of the Sacred Heart / Università Cattolica del Sacro Cuore
Italy (IT)
Beaujon Hospital / Hôpital Beaujon
France (FR)
How to cite
APA:
Cwikla, J.B., Wolin, E.M., Pavel, M.E., Phan, A.T., Raderer, M., Sedlackova, E.,... Caplin, M. (2017). Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension.
MLA:
Cwikla, J. B., et al. "Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide autogel/depot 120mg in the CLARINET open-label extension." 2017.
BibTeX: Download